5-MAPB
Viewing r1 — Apr 21, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) is a synthetic empathogen of the benzofuran class.[1] It is the N-methyl structural analog of 5-APB, related to that compound the way MDMA relates to MDA. It floods synapses with serotonin, dopamine, and norepinephrine,[2] producing emotional warmth and physical energy with a more stimulant-forward character than MDMA.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, MDA, 5-APB +4 moreMDMA, MDA, 5-APB, 6-APB, 6-MAPB, amphetamine, methamphetamine show less
5-MAPB appeared on the research chemical market around 2011–2012 as part of a wave of benzofuran compounds sold as "benzofury" — gray-market alternatives to MDMA.[3] The first pharmacological study was published in 2015, and subsequent research flagged the class as a candidate for PTSD therapeutic development.[4] It is now controlled in the United Kingdom and Germany, with variable legal status in other countries.
Subjective effects include euphoria, emotional closeness, mood elevation, stimulation, and mild perceptual enhancement.[5] The experience is more energized and less dreamy than MDMA — warm and empathogenic at its core, but with a stimulant drive that makes it feel cleaner and more alert. Post-use mood disruption, a strong compulsive redosing urge, and cardiovascular strain are the most characteristic downsides.
Physical dependence is not documented, and no death has been attributed to 5-MAPB alone.[6] The main dangers are cardiovascular strain and serotonin overload — combining with monoamine oxidase inhibitors is potentially lethal,[7] and repeated use raises concern for heart valve damage.[3] No controlled human study has been published; current understanding rests on laboratory data, animal models, and a small number of clinical cases.
History[edit]
Discovery and market emergence
5-MAPB entered the research chemical market around 2011–2012 alongside 5-APB, 6-APB, and 6-MAPB, all sold under the shared "benzofury" brand as gray-market alternatives to MDMA. No original discoverer has been identified in the peer-reviewed literature.citation needed
Research characterization
The first pharmacological characterization appeared in 2015, establishing monoamine transporter interaction profiles for the class.[3] That same year, metabolism in rat models and the compound's presence in human plasma were confirmed.[1] Subsequent receptor binding studies identified 5-MAPB and related compounds as candidates for PTSD therapeutic research.[4]
Regulatory response and modern status
The United Kingdom issued a Temporary Class Drug Order in 2013,[8] followed by permanent Class B scheduling in 2014.[9] Germany brought benzofurans under control in 2016. Academic interest continues through behavioral pharmacology[10] and medicinal chemistry,[11] but no clinical trial has been initiated.
The name "benzofury" — combining "benzofuran" and "fury" — was a vendor marketing term applied to 5-APB, 6-APB, 5-MAPB, and 6-MAPB regardless of their distinct pharmacological profiles. This branding collapsed four different compounds into one identity, contributing to dosing confusion among users. The aminoalkylbenzofuran scaffold is a textbook example of bioisosteric replacement in recreational drug design: swapping MDMA's methylenedioxy bridge for a fused furan ring preserves the entactogenic character while changing receptor selectivity and metabolic fate.[12]
Chemistry[edit]
Structural class
5-MAPB belongs to the aminoalkylbenzofuran family — compounds structurally related to MDMA, with its characteristic ring system replaced by a benzofuran structure.[12]
Within that family, it is the N-methyl structural analog of 5-APB, sharing the same structural relationship as methamphetamine to amphetamine.[1] Its molecular formula is C₁₂H₁₅NO (molecular weight 189.25 g/mol), most commonly encountered as the hydrochloride salt.
Molecular properties
| Molecular formula | C₁₂H₁₅NO (free base) |
| Molecular weight | 189.25 g/mol (free base) |
Pharmacology[edit]
Mechanism of action
5-MAPB works identically to MDMA: it reverses monoamine transporters, causing serotonin, dopamine, and norepinephrine to flood the synapse.[3] Its release profile is more balanced than MDMA's — less serotonin-dominant, with relatively stronger dopamine and norepinephrine contributions.[2]
5-MAPB also directly activates serotonin receptors beyond releasing serotonin.[4] One receptor pathway, when activated repeatedly, causes heart valve thickening — the same mechanism seen with fenfluramine.[3] Preliminary data suggest MAO-A inhibition as well,[4] which would amplify serotonergic effects — but this finding remains unconfirmed.
Pharmacokinetics
No controlled human pharmacokinetic study has been published — half-life, bioavailability, and peak plasma time are unknown. The body metabolizes 5-MAPB primarily into 5-APB,[1] an active compound in its own right, meaning effects may outlast the parent compound's clearance.
Neuroscience[edit]
Where it acts
Releasing serotonin, dopamine, and norepinephrine simultaneously reduces threat reactivity, strengthens emotional regulation via prefrontal-amygdala communication, and triggers oxytocin release[3][10] — the neural basis of the emotional openness and reduced social anxiety that define the entactogenic experience.
The stronger dopamine contribution compared to MDMA[2] predicts greater activation of reward circuitry, accounting for the more pronounced euphoria and stronger redosing urge. Norepinephrine release drives the stimulant dimension — elevated heart rate, alertness, and peripheral vasoconstriction.[4]
Why it matters
Entactogens are theorized to open a window for processing traumatic memories — reduced fear response, enhanced prefrontal regulation, and elevated social trust create conditions where difficult emotional material can be approached without overwhelming distress.[4] This is the rationale for examining benzofurans as potential PTSD therapeutics.
Key unresolved questions include whether 5-MAPB causes serotonergic neurotoxicity with repeated use (expected by class analogy with MDMA but never directly studied), whether the preliminary MAO-A inhibition finding[4] represents a meaningful departure from MDMA's pharmacology, and whether chronic serotonin receptor activation causes heart valve changes in human users.[3] The contribution of the active metabolite 5-APB to any neurotoxic process, and potential enantioselective neural effects inferred from related compounds,[11] remain entirely uncharacterized.
Subjective Effects[edit]
5-MAPB delivers the core entactogenic signature — emotional warmth, social closeness, and bodily euphoria — on a more stimulant-forward chassis than MDMA. Comfortable social environments draw out its empathogenic warmth; adverse or overstimulating contexts can shift the experience toward anxiety and agitation.
Compared to MDMA, users describe 5-MAPB as cleaner and more energized — less of MDMA's dreamy serotonergic heaviness. Compared to MDA, it produces noticeably less perceptual distortion: the experience stays in social-emotional space rather than drifting toward psychedelic territory.
Effect Grid
At common doses (60–80 mg oral), the full entactogenic experience manifests: pronounced euphoria, strong emotional closeness with others, enhanced empathy, and significant music enhancement. Thought acceleration and focus enhancement become prominent. Visual acuity may sharpen and colors appear more vivid, though frank visual distortions are not characteristic at this range.
Physically, stimulation is substantial — increased heart rate, excessive sweating, jaw tension (bruxism), and pupil dilation are typical. Nausea during the come-up is common. Appetite suppression is near-complete. Dehydration risk increases with physical activity.
Sleep is impossible for 5–8 hours. The full experience commits the user for an evening. Compulsive redosing urges may emerge as the peak begins to wane.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Color alteration · Visual acuity enhancement · Visual processing acceleration · Brightness alteration · Geometry · Proprioceptive distortion · Tracers · Visual breathing · Visual drifting · Visual haze / noise · Olfactory enhancement · Taste enhancement · Visual morphing · After-images · Auditory distortion · Auditory misinterpretation · Depth perception distortion · Environmental patterning · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Symmetrical texture repetition · Synesthesia · Tinnitus · Vestibular distortion · Visual diffraction · Visual melting · Flashbacks · Object transformations · Environmental orbism / cubism · External hallucinations · Internal hallucinations · Object activation · Persisting hallucinations · Perspective hallucinations
Brightness alteration · Geometry · Proprioceptive distortion · Tracers · Visual breathing · Visual drifting · Visual haze / noise · Olfactory enhancement · Taste enhancement · Visual morphing · After-images · Auditory distortion · Auditory misinterpretation · Depth perception distortion · Environmental patterning · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Symmetrical texture repetition · Synesthesia · Tinnitus · Vestibular distortion · Visual diffraction · Visual melting · Flashbacks · Object transformations · Environmental orbism / cubism · External hallucinations · Internal hallucinations · Object activation · Persisting hallucinations · Perspective hallucinations
Body scan awareness · Appetite suppression · Wakefulness · Pupil dilation · Tactile euphoria · Dehydration sensation · Excessive sweating · Nystagmus (eye wobbles) · Bruxism · Dry mouth · Insomnia · Physical fatigue · Tingling / electric sensations · Heart rate perception changes · Muscle tension · Nausea · Sexual arousal suppression · Bodily lightness · Headache · Laughter fits · Muscle relaxation · Pain suppression · Restlessness · Sexual arousal enhancement · Vibrations / buzzing · Bodily pressures · Breathing alteration · Dizziness · Respiratory stimulation · Trembling · Abnormal heartbeat · Body schema distortion · Brain zaps · Diarrhea · Involuntary body movements · Nasal congestion · Vomiting · Watery eyes · Yawning
Pupil dilation · Tactile euphoria · Dehydration sensation · Excessive sweating · Nystagmus (eye wobbles) · Bruxism · Dry mouth · Insomnia · Physical fatigue · Tingling / electric sensations · Heart rate perception changes · Muscle tension · Nausea · Sexual arousal suppression · Bodily lightness · Headache · Laughter fits · Muscle relaxation · Pain suppression · Restlessness · Sexual arousal enhancement · Vibrations / buzzing · Bodily pressures · Breathing alteration · Dizziness · Respiratory stimulation · Trembling · Body schema distortion · Brain zaps · Diarrhea · Involuntary body movements · Nasal congestion · Vomiting · Watery eyes · Yawning
Cognitive fatigue · Aesthetic enhancement · Thought acceleration · Immersion enhancement · Novelty enhancement · Thought connectivity · Motivation enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language enhancement · Memory replays · Pattern recognition enhancement · Suggestibility enhancement · Focus enhancement · Analysis enhancement · Information processing enhancement · Motivation suppression · Cognitive impairment · Multiple thought streams · Thought loops · Thought organization · Thought deceleration · Confusion · Memory fragmentation · Memory suppression · Synchronicity · Thought disorganization · Memory enhancement
Immersion enhancement · Novelty enhancement · Thought connectivity · Motivation enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language enhancement · Memory replays · Pattern recognition enhancement · Focus enhancement · Analysis enhancement · Information processing enhancement · Motivation suppression · Cognitive impairment · Multiple thought streams · Thought loops · Thought organization · Thought deceleration · Confusion · Memory fragmentation · Memory suppression · Synchronicity · Thought disorganization · Memory enhancement
Anxiety suppression · Irritability · Catharsis · Emotional lability · Simultaneous emotions · Anhedonia · Anxiety · Dysphoria
Simultaneous emotions · Anhedonia · Anxiety · Dysphoria
Sociability enhancement · Disinhibition · Emotional susceptibility · Flow state · Automaticity · Craving · Depersonalization · Derealization · Ego inflation · Boundary dissolution · Telepathic feelings · Ego dissolution
Automaticity · Craving · Depersonalization · Derealization · Ego inflation · Boundary dissolution · Telepathic feelings · Ego dissolution
Time cessation
Timeline
First alerts emerge as subtle mood shift and mild physical awareness — slight warmth, gentle arousal of attention. Easily mistaken for anticipatory excitement.
Effects build steadily: mood elevation becomes unmistakable, sociability increases, and physical stimulation rises. Nausea is most likely during this phase. Heart rate and pupil dilation increase noticeably.
Full entactogenic experience: pronounced euphoria, emotional closeness, music enhancement, and thought acceleration. Physical stimulation is maximal — sweating, jaw tension, tachycardia. Compulsive redosing urges may emerge as the peak begins to plateau.
Intensity gradually recedes from peak levels but core entactogenic effects persist. Emotional warmth and sociability remain. Physical stimulation begins to ease.
Gentle return toward baseline. Mood remains mildly elevated or transitions toward fatigue. Residual stimulation may make relaxation difficult.
Residual effects span a wide range: some experience mild mood elevation and reflective clarity; others encounter fatigue, irritability, depressed mood, and cognitive sluggishness from monoamine depletion. Duration and character depend heavily on dose and individual neurochemistry.
⚠ Do not drive or operate machinery until after a full night of sleep following the experience, as residual stimulation and impaired concentration may persist.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- MDMA · MDA · 5-APB
Toxicity
No lethal dose has been established for 5-MAPB in any species, and no human death has been attributed to 5-MAPB alone. The single published fatality involved polydrug co-intoxication with AMT, benzodiazepines, and sympathomimetic agents.[6] Clinical cases showed plasma levels of 5–124 μg/L without reported organ damage.[1]
Cardiovascular effects
Norepinephrine and dopamine release raises heart rate, elevates blood pressure, and constricts blood vessels.[13] Additional receptor binding[4] may amplify cardiovascular stress beyond what transporter release alone predicts.
Chronic cardiac risk: Repeated exposure raises theoretical concern for heart valve thickening through serotonin receptor activation — the same mechanism that caused valve disease in fenfluramine users.[3] No 5-MAPB cases have been documented, but no long-term studies have looked.
Overheating
Dangerously elevated body temperature is a class-level risk for serotonin and dopamine releasing agents — particularly in hot environments, during physical exertion, or with inadequate hydration.[13] No 5-MAPB-specific case has been published, but the risk is established by mechanism.
Neurotoxicity
No neurotoxicity study specific to 5-MAPB has been conducted. By class analogy with MDMA and MDA, heavy repeated use carries theoretical risk of lasting damage to serotonin-producing nerve endings. The contribution of the active metabolite 5-APB to any neurotoxic process is unknown.
Psychological risks
Anxiety, agitation, and paranoia may occur at high doses or in adverse settings. Post-use low mood, irritability, and mental fatigue follow from monoamine depletion after the acute surge[13] — severity increases with higher doses or redosing within a session.
Compulsive redosing is a recognized behavioral risk. The strong dopamine release[2] drives re-administration urges as serotonergic warmth fades. Paranoia, hallucinations, and delusional thinking have been reported in case series involving stimulant/entactogen polydrug use or pre-existing psychiatric vulnerability.[14]
Tolerance and dependence
Tolerance develops with repeated use through SERT downregulation and monoamine depletion, consistent with the MDMA class pattern.inferred Cross-tolerance with MDMA, MDA, and amphetamines is expected based on shared mechanisms.
5-MAPB fully substitutes for MDMA in drug discrimination studies at more potent doses,[10] confirming abuse potential. Strong dopamine release[2] predicts psychological dependence; physical dependence liability is expected to be low based on MDMA class patterns. No human dependence cases have been published.
Drug interactions
Combining 5-MAPB with monoamine oxidase inhibitors is the highest-risk interaction. MAO inhibitors prevent serotonin breakdown, and 5-MAPB releases serotonin in large amounts — the combination can produce lethal accumulation. Deaths from MDMA combined with moclobemide are documented,[7][15] and the same mechanism applies. Preliminary evidence suggests 5-MAPB may also inhibit MAO-A,[4] which would compound the risk further.
Tramadol,safety citation needed SSRIs, SNRIs, and lithiumsafety citation needed all raise serotonin levels, increasing overload risk when combined with 5-MAPB. SSRIs may also blunt the desired effects while paradoxically raising serotonin syndrome risk.
Other stimulants — MDMA, amphetamines, cocaine, ephedrine — produce additive cardiovascular strain. The fatal polydrug case included ephedrine.[6] CYP2B6 inhibitors (ticlopidine, clopidogrel) increase 5-MAPB plasma levels by slowing clearance; CYP2B6 inducers (rifampicin, carbamazepine) reduce levels and shift the metabolite ratio.[1]
Contraindications
Absolute contraindications
- Concurrent MAO inhibitor use — irreversible (phenelzine, tranylcypromine) or reversible (moclobemide). Fatal serotonin syndrome risk.[7][15]
- Concurrent serotonergic agent use (tramadol, SSRIs, SNRIs, other serotonin releasers) — elevated serotonin syndrome risk.
Relative contraindications
- Heart conditions — the sympathomimetic mechanism poses risk for pre-existing cardiac disease, high blood pressure, or irregular heartbeat.
- Liver impairment — CYP2B6-dependent metabolism means impaired liver function increases drug exposure.
- Psychiatric vulnerability — personal or family history of psychotic disorders, bipolar disorder, or severe anxiety disorders.
- Pregnancy and breastfeeding — no reproductive toxicity data; contraindicated based on class-level risk.safety citation needed
- CYP2B6/CYP2D6 poor metabolizer status — elevated plasma exposure and altered metabolite ratios.[1]
Harm Reduction[edit]
Forms & Identification
5-MAPB is sold as a white to off-white crystalline powder in its hydrochloride form. The benzofuran series presents a specific identification challenge: 5-MAPB, 5-APB, 6-APB, and 6-MAPB are visually indistinguishable and were sold under the same "benzofury" brand regardless of contents.
Reagent testing can confirm a benzofuran compound is present but may not distinguish between positional isomers within the series. Quantitative laboratory analysis is the only reliable method for confirming specific identity.
Guidelines
- Test every batch with reagent kits before use — confirm the substance is a benzofuran rather than an unrelated compound at minimum
- Start with a low dose and wait at least 90 minutes before considering redosing — onset can be slow, and redosing is a recognized risk with this compound
- Have a sober, trusted person present who knows what was taken and when
- Stay cool and hydrated — drink water at a moderate pace (not excessively), take breaks from physical activity, and move to cooler areas if body temperature feels elevated
- Avoid combining with other stimulants, serotonergic drugs, or monoamine oxidase inhibitors
- Do not use on consecutive days — allow extended recovery windows between sessions to minimize monoamine depletion and neurotoxicity risk
- Eat a light meal beforehand and have easily digestible food available afterward
Set & Setting
The entactogenic effects are strongly context-dependent. Comfortable, familiar environments with trusted companions draw out the emotional warmth and social openness; loud, crowded, or unfamiliar settings increase anxiety and overstimulation. Physical activity and heat compound the risk of overheating and dehydration — the stimulant character makes it easy to exceed normal physical limits without noticing.
Aftercare & integration. Monoamine depletion after a 5-MAPB session — especially serotonin — commonly produces low mood, irritability, and mental fatigue beginning one to two days after use and lasting several days. This is neurochemically expected, not a sign of damage.
Prioritize sleep, nutritious food, gentle activity, and social connection in the days following use. Avoid making major decisions during the low-mood period — it does not reflect baseline mental state. If emotional material surfaced during the experience, journaling or conversation with a trusted person can help integrate insights before they fade.
Recovery & Support
Compulsive redosing and escalating frequency of use are the primary warning signs of a problematic relationship with 5-MAPB or related entactogens. If doses are increasing to chase diminishing effects, or use continues despite negative consequences, professional support is warranted.
Resources include substance-specific harm reduction organizations, addiction counselors familiar with stimulant and entactogen patterns, and peer support communities. The psychological nature of entactogen dependence — distinct from the physical withdrawal of opioids or alcohol — responds well to behavioral and therapeutic approaches.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help for any of the following: chest pain or pressure, seizure, loss of consciousness, body temperature hot enough to feel through clothing, confusion or inability to communicate, or signs of serotonin syndrome (rigid muscles, rapid heartbeat, agitation, high fever).
Immediate steps:
- 1. Call emergency services immediately if the person is unconscious, seizing, having chest pain, or dangerously overheated
- 2. Place an unconscious but breathing person in the recovery position (on their side)
- 3. Move to a cool area and apply cold compresses if overheating is suspected
- 4. Do not leave the person alone
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (5-MAPB), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
5-MAPB is explicitly controlled in the United Kingdom and Germany; elsewhere, legal status ranges from unscheduled to potentially covered by structural analog legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B (Schedule 1) | TCDO issued 2013 on ACMD advice;[8] permanently scheduled 2014 under SI 2014/1106 covering all aminoalkylbenzofuran derivatives;[9] additionally covered by Psychoactive Substances Act 2016 |
| Germany | Controlled (NpSG) | Covered under the Neue-psychoaktive-Stoffe-Gesetz effective November 2016; benzofuran class included in structural coverage |
| Sweden | Scheduled narcotic | Classified as a narcotic substance; year of scheduling not confirmed from primary sourcecitation needed |
| United States | Not individually scheduled | Not listed in DEA Schedules I–V. Federal Analogue Act (21 U.S.C. § 813) may apply as a structural and pharmacological analog of MDMA and MDA (both Schedule I); requires case-by-case determinationcitation needed |
| European Union | Variable | Monitored by EUDA (formerly EMCDDA) as an NPS; individual member state scheduling varies. Class-wide NPS legislation in some states |
| Australia | Not confirmed | TGA scheduling status unverified from primary sourcessafety citation needed |
| Canada | Not confirmed | CDSA scheduling status unverified from primary sourcessafety citation needed |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current status in any applicable jurisdiction before acting on it.
Analog act considerations
In jurisdictions with analog legislation — notably the United States — 5-MAPB's structural similarity to MDMA (Schedule I) and MDA (Schedule I) and its full MDMA substitution in drug discrimination[10] provide the basis for prosecution under the Federal Analogue Act.[3] Prosecution outcomes depend on case-specific factors including intent of use and expert testimony on pharmacological similarity.
references
- [1] ^abcdefgWelter J, Kavanagh P, Meyer MR, Maurer HH (2015) Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-014-8360-0
- [2]
- [3]
- [4]
- [5] ^Barcelo B, Gomila I, Rotolo MC, Marchei E, Kyriakou C, Pichini S, Roset C, Elorza MA, Busardo FP (2017) Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate — International Journal of Legal Medicine doi:10.1007/s00414-017-1648-9
- [6] ^abcEpain M, Cartiser N, Bevalot F, Bottinelli C, Chatenay C, Fanton L (2024) Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature — International Journal of Legal Medicine doi:10.1007/s00414-024-03236-w